Current neoadjuvant treatment options for HER2 positive breast cancer

Hikmat Abdel-Razeq, Lina MareiSection of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman, JordanAbstract: Approximately one quarter of patients with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, the exp...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abdel-Razeq H, Marei L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fc642340cbf748b88e9d594db1cc3e9c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fc642340cbf748b88e9d594db1cc3e9c
record_format	dspace
spelling	oai:doaj.org-article:fc642340cbf748b88e9d594db1cc3e9c2021-12-02T07:09:33ZCurrent neoadjuvant treatment options for HER2 positive breast cancer1177-54751177-5491https://doaj.org/article/fc642340cbf748b88e9d594db1cc3e9c2011-08-01T00:00:00Zhttp://www.dovepress.com/current-neoadjuvant-treatment-options-for-her2-positive-breast-ca-a8042https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Hikmat Abdel-Razeq, Lina MareiSection of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman, JordanAbstract: Approximately one quarter of patients with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, the expression of which is associated with a relatively poor prognosis independent of other clinical and pathologic variables. Trastuzumab, a humanized recombinant monoclonal antibody specifically directed against the HER2 receptor, has been shown to be biologically active and of considerable clinical utility in HER2-positive breast cancer patients. Neoadjuvant chemotherapy has been used in breast cancer to downstage the tumor and increase the opportunity for breast-conserving surgery. Preoperative chemotherapy can also serve as an in vivo testing of chemotherapy sensitivity. Additionally, a pathologic complete response is usually a surrogate marker of disease-free survival. Following the successful use of trastuzumab in the metastatic and adjuvant settings, many clinical trials have recently reported the successful use of anti-HER2 therapy in combination with different chemotherapy regimens in the neoadjuvant setting with a significantly higher pathologic complete response. With the recent introduction of new anti-HER2 drugs, interest has shifted toward dual HER2 blockade. Two such studies were recently reported, both showing a significant advantage of dual anti-HER2 therapy using lapatinib or pertuzumab in addition to trastuzumab and chemotherapy. However, several key questions need to be investigated further, such as the preferred combination chemotherapy and the optimal duration of trastuzumab in patients who achieve a pathologic complete response following preoperative chemotherapy with trastuzumab. These issues and others are discussed in this review.Keywords: neoadjuvant, breast cancer, trastuzumab, pertuzumab, lapatinibAbdel-Razeq HMarei LDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2011, Iss default, Pp 87-94 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Abdel-Razeq H Marei L Current neoadjuvant treatment options for HER2 positive breast cancer
description	Hikmat Abdel-Razeq, Lina MareiSection of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman, JordanAbstract: Approximately one quarter of patients with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, the expression of which is associated with a relatively poor prognosis independent of other clinical and pathologic variables. Trastuzumab, a humanized recombinant monoclonal antibody specifically directed against the HER2 receptor, has been shown to be biologically active and of considerable clinical utility in HER2-positive breast cancer patients. Neoadjuvant chemotherapy has been used in breast cancer to downstage the tumor and increase the opportunity for breast-conserving surgery. Preoperative chemotherapy can also serve as an in vivo testing of chemotherapy sensitivity. Additionally, a pathologic complete response is usually a surrogate marker of disease-free survival. Following the successful use of trastuzumab in the metastatic and adjuvant settings, many clinical trials have recently reported the successful use of anti-HER2 therapy in combination with different chemotherapy regimens in the neoadjuvant setting with a significantly higher pathologic complete response. With the recent introduction of new anti-HER2 drugs, interest has shifted toward dual HER2 blockade. Two such studies were recently reported, both showing a significant advantage of dual anti-HER2 therapy using lapatinib or pertuzumab in addition to trastuzumab and chemotherapy. However, several key questions need to be investigated further, such as the preferred combination chemotherapy and the optimal duration of trastuzumab in patients who achieve a pathologic complete response following preoperative chemotherapy with trastuzumab. These issues and others are discussed in this review.Keywords: neoadjuvant, breast cancer, trastuzumab, pertuzumab, lapatinib
format	article
author	Abdel-Razeq H Marei L
author_facet	Abdel-Razeq H Marei L
author_sort	Abdel-Razeq H
title	Current neoadjuvant treatment options for HER2 positive breast cancer
title_short	Current neoadjuvant treatment options for HER2 positive breast cancer
title_full	Current neoadjuvant treatment options for HER2 positive breast cancer
title_fullStr	Current neoadjuvant treatment options for HER2 positive breast cancer
title_full_unstemmed	Current neoadjuvant treatment options for HER2 positive breast cancer
title_sort	current neoadjuvant treatment options for her2 positive breast cancer
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/fc642340cbf748b88e9d594db1cc3e9c
work_keys_str_mv	AT abdelrazeqh currentneoadjuvanttreatmentoptionsforher2positivebreastcancer AT mareil currentneoadjuvanttreatmentoptionsforher2positivebreastcancer
_version_	1718399612659695616

Current neoadjuvant treatment options for HER2 positive breast cancer

Ejemplares similares